Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TP53 | P04637 | 5/20 | 0.35 |
| ▸ | GNRHR | P30968 | 2/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.33 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.33 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
| ▸ | PDE5A | O76074 | 1/20 | 0.32 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.32 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.32 |
| ▸ | EGFR | P00533 | 2/20 | 0.31 |
| ▸ | SDHB | P21912 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30526107 | 1.00 | TP53 (0.35) | TP53GNRHRKMT2AMAPK1HSD17B10 | |
| SCHEMBL19806107 | 0.94 | GNRHR (0.36) | TP53GNRHRKMT2AHSD17B10MEN1 | |
| SCHEMBL30526076 | 0.94 | GNRHR (0.36) | TP53GNRHRKMT2AHSD17B10MEN1 | |
| SCHEMBL19806023 | 0.91 | GNRHR (0.36) | TP53GNRHRKMT2AMAPK1HSD17B10 | |
| SCHEMBL29976275 | 0.91 | GNRHR (0.36) | TP53GNRHRKMT2AMAPK1HSD17B10 | |
| SCHEMBL21019479 | 0.90 | TP53 (0.34) | TP53GNRHRKMT2AHSD17B10ALDH1A1 | |
| SCHEMBL21019774 | 0.90 | GNRHR (0.34) | TP53GNRHRKMT2AHSD17B10ALDH1A1 | |
| SCHEMBL21019917 | 0.90 | GNRHR (0.34) | TP53GNRHRKMT2AHSD17B10MEN1 | |
| SCHEMBL21020135 | 0.89 | ALDH1A1 (0.33) | TP53GNRHRKMT2AMAPK1HSD17B10 | |
| SCHEMBL29976196 | 0.89 | SDHB (0.32) | GNRHRSDHB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11725000-B2 | Apoptosis inhibitors | NATIONAL INSTITUTE OF BIOLOGICAL SCIENCES, BEIJING (CN) | 2023-08-15 | — | — | US | disclosed |
| US-11725000-B2 | Apoptosis inhibitors | NATIONAL INSTITUTE OF BIOLOGICAL SCIENCES, BEIJING (CN) | 2023-08-15 | — | — | US | disclosed |
| US-11725000-B2 | Apoptosis inhibitors | NATIONAL INSTITUTE OF BIOLOGICAL SCIENCES, BEIJING (CN) | 2023-08-15 | — | — | US | disclosed |
| CN-110023292-B | Apoptosis inhibitors | 北京生命科学研究所 | 2022-10-04 | — | — | CN | disclosed |
| US-20210309647-A1 | Apoptosis Inhibitors | NATIONAL INSTITUTE OF BIOLOGICAL SCIENCES, BEIJING (CN) | 2021-10-07 | — | — | US | disclosed |
| US-20210309647-A1 | Apoptosis Inhibitors | NATIONAL INSTITUTE OF BIOLOGICAL SCIENCES, BEIJING (CN) | 2021-10-07 | — | — | US | disclosed |
| US-11034680-B2 | Apoptosis inhibitors | NATIONAL INSTITUTE OF BIOLOGICAL SCIENCES, BEIJING (CN) | 2021-06-15 | — | — | US | disclosed |
| US-11034680-B2 | Apoptosis inhibitors | NATIONAL INSTITUTE OF BIOLOGICAL SCIENCES, BEIJING (CN) | 2021-06-15 | — | — | US | disclosed |
| EP-3484854-B1 | APOPTOSIS INHIBITORS | NAT INSTITUTE OF BIOLOGICAL SCIENCES BEIJING (CN) | 2021-01-20 | — | — | EP | disclosed |
| EP-3484854-B1 | APOPTOSIS INHIBITORS | NAT INSTITUTE OF BIOLOGICAL SCIENCES BEIJING (CN) | 2021-01-20 | — | — | EP | disclosed |
| US-20190152960-A1 | Apoptosis Inhibitors | NATIONAL INSTITUTE OF BIOLOGICAL SCIENCES, BEIJING (CN) | 2019-05-23 | — | — | US | disclosed |
| US-20190152960-A1 | Apoptosis Inhibitors | NATIONAL INSTITUTE OF BIOLOGICAL SCIENCES, BEIJING (CN) | 2019-05-23 | — | — | US | disclosed |
| WO-2018014802-A1 | APOPTOSIS INHIBITORS | NATIONAL INSTITUTE OF BIOLOGICAL SCIENCES, BEIJING (CN) | 2018-01-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190152960-A1 | Apoptosis Inhibitors | BAX, SDHA, SDHB | TP53 160/4885GNRHR 3014/4885KMT2A 3060/4885 |
| US-11725000-B2 | Apoptosis inhibitors | BAX, SDHA, SDHB | TP53 160/4885GNRHR 3014/4885KMT2A 3060/4885 |
| US-11034680-B2 | Apoptosis inhibitors | BAX, SDHA, SDHB | TP53 160/4885GNRHR 3014/4885KMT2A 3060/4885 |
| US-20210309647-A1 | Apoptosis Inhibitors | BAX, SDHA, SDHB | TP53 160/4885GNRHR 3014/4885KMT2A 3060/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.